Among the drugs that inhibit the recruitment of TAMs, the CSF-1R inhibitor pexidartinib in clinical trials has excellent clinical benefits in solid tumors such as in tenosynovial giant-cell tumors (TGCT), unresectable sarcoma, and malignant peripheral nerve sheath tumors. Here, CSF1R is linked to sarcoma.